These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32852167)

  • 21. Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.
    Morillas C
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():49-53. PubMed ID: 28760226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R; Davis TM; Ekinci EI
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of publishing medical specialty society guidelines on subsequent adoption of best practices: a case study with type 2 diabetes.
    Huang EA; Zdon GS; Moore RJ; Jane Moran H; Quick WW
    Int J Clin Pract; 2010 Apr; 64(5):558-61. PubMed ID: 20456210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Zealand may finally get funded access to diabetes drugs which reduce cardiovascular events and progression of kidney disease: an audit of proposed PHARMAC criteria compared with international guidelines.
    Vitz M; Moss B; Ward H; Soma P; Isichei-Kizito J; Hall R; Krebs J
    N Z Med J; 2020 Oct; 133(1523):76-86. PubMed ID: 33032305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes medications and cardiovascular disease: at long last progress.
    Lupsa BC; Inzucchi SE
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):87-93. PubMed ID: 29369916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [DPP-4 or SGLT2 inhibitor added to metformin alone in type 2 diabetes].
    Paquot N; Scheen AJ
    Rev Med Suisse; 2017 Aug; 13(571):1410-1415. PubMed ID: 28837277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ; Aroda VR; Collins BS; Gabbay RA; Green J; Maruthur NM; Rosas SE; Del Prato S; Mathieu C; Mingrone G; Rossing P; Tankova T; Tsapas A; Buse JB
    Diabetes Care; 2022 Nov; 45(11):2753-2786. PubMed ID: 36148880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Making sense of newer treatment options for type 2 diabetes.
    Lee PC; Hare MJL; Bach LA
    Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison.
    Kelsey MD; Nelson AJ; Green JB; Granger CB; Peterson ED; McGuire DK; Pagidipati NJ
    J Am Coll Cardiol; 2022 May; 79(18):1849-1857. PubMed ID: 35512864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view.
    Scheen AJ
    Diabetes Res Clin Pract; 2020 Jan; 159():107726. PubMed ID: 31108136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.
    Chang LS; Vaduganathan M; Plutzky J; Aroda VR
    Curr Diab Rep; 2019 Dec; 19(12):157. PubMed ID: 31802265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New ESC guidelines 2019 "Diabetes, prediabetes and cardiovascular diseases" : Paradigm shift in reduction of cardiovascular risk in patients with diabetes mellitus].
    Marx N
    Herz; 2019 Dec; 44(8):684-687. PubMed ID: 31686123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint ESC/EASD guidelines on diabetes, where are we now and where should we go?
    Rydén L; Mellbin L
    Curr Vasc Pharmacol; 2012 Nov; 10(6):690-2. PubMed ID: 23259555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of antidiabetic drugs.
    Sørensen AM; Christensen MB
    Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New oral antidiabetic drugs].
    Féry F
    Rev Med Brux; 2014 Sep; 35(4):347-55. PubMed ID: 25675642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.